ПОБОЧНЫЕ ЭФФЕКТЫ АНТИЭПИЛЕПТИЧЕСКОЙ ТЕРАПИИ
https://doi.org/10.17749/2077-8333.2017.9.1.051-061
Аннотация
Зачастую использование антиэпилептических препаратов ассоциируется с риском развития нежелательных явлений, непосредственно влияющих на переносимость и успех лечения в целом. Пациенты с выраженными нежелательными явлениями вынуждены преждевременно прекращать лечение или менять лекарственный препарат. Долговременная стратегия ведения пациентов с таким длительно текущим заболеванием, как эпилепсия, должна включать не только достижение контроля над приступами, но и максимально раннее выявление нежелательных явлений, предупреждение, прогнозирование и минимизацию проявлений побочных эффектов. Это позволит улучшить приверженность к лечению, качество жизни пациентов и достигнуть контроля над эпилепсией.
Об авторе
И. Ю. Ковалева
ФГБОУ ВО «РНИМУ им. Н. И. Пирогова» Минздрава России
Россия
Россия
Ковалева Ирина Юрьевна – кандидат медицинских наук, профессор кафедры неврологии, нейрохирургии и медицинской генетики лечебного факультета.
Ул. Островитянова, д. 1, Москва, 117997, Тел.: +7(495)4343690
Список литературы
1. Воронкова К. В., Петрухин А. С. и соавт. Рациональная антиэпилептическая терапия. М. 2008; 191 с.
2. Карлов В. А. Эпилепсия у детей и взрослых мужчин и женщин Руководство для врачей. М. 2010; 718 с.
3. Banerjee P. N., Filippi D., Hauser W. A. The descriptive epidemiology of epilepsy: a review. Epilepsia. 2009; 85 (1): 31-45.
4. Joannessen Landmark C., Larsson P. G. et al. Antiepileptic drugs in epilepsy and other disoders: a population-based study of prescriptions. Epilepsy Res. 2009; 87 (1): 31-9.
5. Гусев Е. И., Белоусов Ю. Б., Гехт А. Б. и соавт. Лечение эпилепсии: рациональное дозирование антиконвульсантов. СПб. 2000. 201 с.
6. Зенков Л. Р. Противосудорожная терапия может утяжелять течение эпилепсии. Неврологический журнал. 2007; 12 (3): 8-13.
7. Мухин К. Ю., Петрухин А. С., Рыкова Е. А. Побочные эффекты антиконвульсантов при лечении идиопатической генерализованной эпилепсии. Журнал неврологии и психиатрии. 1997; 7: 25-31.
8. Perucca E. Advers effect of antiepileptic drugs. Focus Farmacovigilanza. 2012; 80 (1): 1.
9. Perucca E. et al. Adverse antiepileptic drug effects: Toward a clinically and neurobiologically relevant taxonomy. Neurology. 2009; 72: 1223-1229.
10. Baker G. A., Middleton A., Jacoby A. et al. Initial development, reliability, and validity of a patient-based adverse event scale. Epilepsia. 1994; 35 (7): 80.
11. Schmitz B., Robertson M., Trimble M. R. Depression and schizophrenia in epilepsy: social and biological risk factors. Epilepsy Res. 1999; 35: 59-68.
12. Herranz J. L., Armijo J. A., Arteaga R. Clinical side effects of phenobarbital, primidon, phenytoin, carbamazepine and valproate in children. Epilepsia. 1988; 29 (6): 794-804.
13. Rosenfield R. L. Clinical practice: hirsuitism. N Engl J Med. 2005; 353 (24): 2578-88.
14. Smith M. C., Centorino F. et al. Clinical comparison of extended-release divaproex versus delaed-release divaproex: pooled data analisis from nine trials. Epilepsy Behav. 2004; 5 (5): 746-51.
15. Koch-Weser J., Browne T. R. Drug therapy: valproic acid. N Engl J Med. 1980; 302 (12): 661-6.
16. Shapiro J. Clinical practice: hair loss in women. N Engl J Med. 2017; 3579160: 1620-30.
17. Tengstrand M et al. Allopecia in association with lamotrigine use: analisis of individual case safety reports in a global database. Drug Saf. 2010; 33 (8): 653-8.
18. Aarli J. A. Phenitoin-induced depression of salivation IgA gingival hyperplasia. Epilepsia. 1976; 17 (3): 283-91.
19. Cerminara C. et al. Hipohydrosis during topiramat treatment: a rare and reversible side effect. Pediatr Neurol. 2006; 34 (5): 392-4.
20. Leppic I. E. Practical prescribing and long-term efficacy and safety of zonisamid. Epilepsia. 2006; 68 (2): 17-24.
21. FDA Safety Communication UCM349847, 24/04/2013.
22. Beniczky S. A., Viken J. et al. Bone mineral density in adult patients treated with varios AEDs. Seizure. 2012; 21 (6): 471-2.
23. Ali I. I., Herial N. A. et al. Measurement of bone minerals density in patient on levetiracetam monotherapy. Epilepsia. 2006; 47 (4): 276.
24. Koo D. L., Yoo E. I. et al. Effect of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patient with epilepsy. Epilepsy Res. 2013; 104 (1-2): 134-9.
25. DeToledo J.C., Toledo C. et al. Changes in body weigh with cronic, high-dose gabapentine therapy. Ther Drug Monit.1997; 19 (4): 394-6.
26. Arroyo S., Anhut H. et al. Pregabaline add-on treatment: a randomized, doubledlinde, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004; 45910: 20-7.
27. Ben-Menachem E. Weght issues for people with epilepsy: a review. Epilepsia. 2007; 48 (9): 42-5.
28. Jallon P., Picard F. Bodyweight gain and anticonvulsants: a comperative review. Drug saf. 2001; 24 (13): 969-78.
29. Biton V., Mirza W. et al. Weigh change association with valproate and lamotrigine in patient with epilepsy. Neurology. 2001; 56 (2): 172-7.
30. Freitag F. G., Collins S. D. et al. A randomize trial of divalproex sodium extended-release tablets in migrein prophilaxis. Neirology. 2002; 58 (11): 1652-9.
31. Privitera M. D., Brodie M. J. et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand. 2003; 107 (3): 165-75.
32. Uludag I. F., Kulu U., Sner U. et al. The effect of carbamazepine treatment on serum leptin levels. Epilepsy Res. 2009; 86 (1): 48-53.
33. Bromley R. L., Leeman B. A., Baker G. A. et al. Cognitive and neurodevelopmental effects of antiepileptic drugs. Epilepsy Behav. 2011; 22 (1): 9-16.
34. Verrotti A., Scaparotta A. et al. Topiramateinduced weght loss: a review. Epilepsy Res. 2011; 95 (3): 189-99.
35. Ben-Menachem E., Axelsen M. et al. Predictors of weight loss in adults with topiramat-treated epilepsy. Obes Res. 2003; 11 (4): 556-62.
36. Eiris J., Novo-Rodriguetz M.I. et al. The effects on lipid and apolipoprotein serum levels on long-term carbamazepine: valproic acide and phenobarbital therapy in children with epilepsy. Epilepsy Res. 2004; 41 (1): 1-7.
37. Galimber ti C. A. et al. Changes in sex steroid level in women with epilepsy on treatment. 2009.
38. Verotti A et al. Antiepileptic drugs, sex hormones and PCOS. 2011; 52 (2): 199-211.
39. Isojarvi J. Disoders of reproduction in patients with epilepsy: antiepileptic drug related mechanisms. 2008.
40. Brodie M. J. et al. Enzime induction with antiepileptic drugs: cause for concern? 2013.
41. Gaitatzis A., Sander J. W. The long-term safety of antiepileptic drugs. CNS Drugs. 2013; 27: 435-455.
42. Matsuura M. Epileptic psychoses and anticonvulsant drug treatment. J Neurol Neurosurg Psychiatry. 1999; 67: 231-3.
43. Mula M., Argawal A., et al. Self-reported aggressivness during treatment with LEV correlates with depression. 2015.
44. Panelli R. J. et al. The Liverpool advers avents profile: relation to AED use and mood. Epilepsia. 2007; 48 (3); 456-463.
45. Brodie M. J., Covanis A., Gil-Nagel A. et al. Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav. 2011; 21 (4): 331-41.
46. Eddy C. M., Rickards H. E., Cavanna A. E. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011; 4 (6): 385-407.
47. Riss J., Cloyd J., Gates J. et al. Benzodiazepines in epilepsy: pharmacology and phamacokinetics. Acta Neurol Scand. 2008; 118 (2): 69-86.
48. Meador K. J., Loring O. W., Moore E. E. et al. Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy adults. Neurology. 1995; 45 (8): 1494-9.
49. Farwell J. R., Lee Y. J., Hirtz D. G. et al. Phenobarbital for febrile seizures: effects on intelligence and on seizure recurrence. N Engl J Med. 1990; 322 (6): 364-9.
50. Arif H., Buchsbaum R., Weintraub D., et al. Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav. 2009; 14 (1): 202-9.
51. White J. R., Walczak T. S., Marino S. E. et al. Zonisamide d due to psychiatric and cognitive adverse events: a case-control study. Neurology. 2010; 75 (6): 513-8.
52. Bootsma H. P., Vos A. M., Hulsman J. et al. Lamotrigine in clinical practice: long-tenn experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav. 2008; 12 (2): 262-8.
53. Marino S. E., Meador K. J., Loring O. W. et al. Subjective perception of cognition is related to mood and not performance. Epilepsy Behav. 2009; 14 (3): 459-64.
54. Luef G., Rauchenzauner M., Waldmann M. et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res. 2009; 86 (1):42-7.
55. Verrotti A., Agostinelli S., Parisi P. et al. Nonalcoholic fatty liver disease in adolescents receiving valproic acid. Epilepsy Behav. 2011; 20 (2): 382-5.
56. Pellock J. M. Felbamate. Epilepsia. 1999; 40(5): 57-2.
57. Koenig S. A., Buesing D., Longin E. et al. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia. 2006; 47 (12): 2027-31.
58. Gram L., Bentsen K. D. Hepatic toxicity of antiepileptic drugs: a review. Acta Neurol Scand Suppl. 1983; 97: 81-90.
59. E. Björnsson. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand. 2008; 118: 281-290.
60. Binek J., Hany A., Heer M. Valproic-acidinduced pancreatitis: case report and review of the literature. J Clin Gastroenterol. 1991; 13 (6): 690-6.
61. Pellock JM, Wilder BJ, Deaton R, et al. Acute pancreatitis coincident with valproate use: a critical review. Epilepsia. 2002; 43 (11): 1421-4.
62. Asconape J. J., Penry J. K., Dreifuss F. E. et al. Valproate-associated pancreatitis. Epilepsia. 1993; 34 (1): 177-83.
63. Buggy Y., Layton D., Fogg C. et al. Safety profile of oxcarbazepine: results from a prescription-event monitoring study. Epilepsia. 2010; 51 (5): 818-29.
64. Letmaier M., Painold A., Holl A. K. et al. Hyponatriaemia during psychopharmacological treatment: results of a drug surveillance progrartune. Int J Neuropsychopharmacol. 2012; 15 (6): 739-48.
65. Dong X., Leppik T. E., White J. et al. Hyponatremia from oxcarbazepine and carbamazepine. Neurology. 2005; 65 (12): 1976-8.
66. Neligan A. et al. The long-term risk of premature mortality in people with epilepsy. Brain. 2011.
67. Bardai A. et al. Sudden cardiac death in associated both with epilepsy and with use of AED. Heart. 2014; 1-6.
68. Weig SG, Pollack P. Carbamazepine-induced heart block in a child with tuberous sclerosis and cardiac rhabdomyoma: implications for evaluation and follow-up. Ann Neurol. 1993; 34 (4): 617-9.
69. DeGiorgio C. M. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav. 2010; 18 (3): 322-4.
70. Zaccara G., Perucca P., Loiacono G. et al. The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2013; 54 (1): 66-74.
71. Danielsson B. R., Lansdell K., Patmore L. et al. Phenytoin and phenobarbital inhibit human HERG potassium channels. Epilepsy Res. 2003; 55 (1-2): 147-57.
72. Danielsson B. R., Lansdell K., Patmore L. et al. Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on bERG potassium currents. Epilepsy Res. 2005; 63 (1): 17-25.
73. Schimpf R., Veltrnann C., Papavassiliu T. et al. Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm. 2012; 9 (5): 776-81.
74. Brodie M. J., Sills G. J., Combining antiepileptic drugsm – Rational polytherapy Seizure. 2011; 20: 369-375.
75. French J. A. Antiepileptic drug treatment. Continuum, Lifelong learning in neurology. Epilepsy. 2013; 643-656.
76. Runge U., Arnold S., Brandt C. et al. A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: VITIBA study. Epilepsia. 2015; 56 (12): 1921-1930.
Рецензия
Для цитирования:
Ковалева И.Ю. ПОБОЧНЫЕ ЭФФЕКТЫ АНТИЭПИЛЕПТИЧЕСКОЙ ТЕРАПИИ. Эпилепсия и пароксизмальные состояния. 2017;9(1):51-61. https://doi.org/10.17749/2077-8333.2017.9.1.051-061
For citation:
Kovaleva I.Yu. ADVERSE EFFECTS OF ANTIEPILEPTIC DRUGS. Epilepsy and paroxysmal conditions. 2017;9(1):51-61. (In Russ.) https://doi.org/10.17749/2077-8333.2017.9.1.051-061
Просмотров:
1900
Контент доступен под лицензией Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Послать статью по эл. почте 
